Science 37 rode the trends of Covid-19 technologies and SPAC mergers to a more than $1 billion valuation. But revenue for the decentralized clinical trials software firm stopped growing, and it’s now going private valued at just $38 million.
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
Creyon Bio is the latest company to launch with artificial intelligence technology for drug R&D. The startup claims its technology can provide sufficient safety and toxicity data to enable a therapy to bypass the animal research currently needed before clinical trials.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
The agency granted an emergency use authorization to the company for its test, which is meant to detect antibodies against SARS-CoV-2 in the blood. However, antibody testing has both advantages and disadvantages relative to the more common PCR assays.
The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,
In June, Quintiles launched a continuous glucose monitoring service, combining consumer wearable devices and medical device CGM to record glucose readings throughout the day.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
CEO of surgical robotics company TransEnterix talks of interactions with FDA that rejected its 510(k) application but refuses to divulge the reason that led to the agency's negative decision frustrating analysts and investors.
New investor Hatteras Venture Partners and existing investor Excelerate Health Ventures co-led the round.
It also projects $5 million in revenue this year.
Forecast Health recently raised $1.45 million from a super angel to grow its national sales team.
The move will help Quintiles improve the frequently costly, lengthy recruitment process for clinical trials.